Close Banner
Open Access Article

June 2020 Newsletter: Discharges During COVID-19, Cardiac Side Effects of Psychotropics, Tobacco Use Disorder, and More

Published on June 20, 2020 Expired on May 15, 2023

Jessica Diaz, M.D.

Associate Director - Psychopharmacology Institute

In this newsletter, we touch on APA’s guidance on the discharge of psychiatric patients during COVID-19; provide interview highlights on the cardiac side effects of psychotropics; and address a few clinical pearls on managing agitation in autism. We also comment on tobacco use disorder and e-cigarettes, as well as 2 article reviews for our Quick Takes: One on tardive dyskinesia and 1 on TMS for OCD.

APA Guidance on Admittance and Discharge of Psychiatric Patients During COVID-19

“It is simply irresponsible to prematurely release patients with serious mental illness from psychiatric inpatient settings into communities ill prepared to treat them,” said APA President Jeffrey Geller, M.D., M.P.H.

This guidance addresses the issue of denying admittance or prematurely releasing psychiatric patients with the pretext of avoiding COVID-19 infection. It states the following:

  • “Premature discharge of patients from psychiatric hospitals and inpatient psychiatric units is unreasonable as this practice exposes patients, families, and the community at large to the risks of harmful and adverse outcomes irrespective of communicable disease outbreaks.”
  • “…referral of patients to any psychiatric setting should balance efforts to match patients’ mental health needs with the appropriate level of care while considering the potential risks of the communicable disease at each level of care.”
  • “Each level of psychiatric care during such outbreaks should provide safe and appropriate treatment…”

Learn more

Expert Consultations: Cardiac Side Effects of Psychiatric Medications With Scott R. Beach, M.D.

In this interview, Dr. Beach discusses the cardiovascular effects of antidepressants, antipsychotics, stimulants, and sleeping aids.

Interview highlights:

  • Venlafaxine may only have a small hypertensive effect at dosages below 300 mg.
  • The risk of sudden cardiac death from an episode of torsade is difficult to estimate, but it may be higher in patients who are silent carriers of QT mutations.
  • It is recommended that patients on stimulants be periodically monitored for changes in heart rate or blood pressure.

Learn more and earn 0.5 CME credits here

Podcast: Case Discussion: Managing Agitation in Autism Spectrum Disorder

A 14-year-old patient with autism spectrum disorder presents to the emergency room with aggressive and agitated behavior. In this podcast episode, Dr. Wegdan Rashad discusses with Dr. Gonzalo Laje (pediatric and adolescent psychiatrist; Chevy Chase, MD) how to work up and manage a clinical case like this.

Key points:

  • Observe for signs of pain that the patient may not be able to verbalize.
  • In a patient with autism and agitation, consider drug-induced causes, like akathisia.
  • Start by reducing sensory stimulation, and then establish a set routine and structure to the day.
  • Consider short-term benzodiazepines or beta-blockers; however, keep in mind the effect beta-blockers have on sleep.

Listen to the full discussion here

Video Lecture: The Clinical Guide on Tobacco Use Disorder

Nicotine and tobacco smoke have noticeable effects in the body. Treatment approaches for smoking cessation include pharmacologic options, such as bupropion, varenicline, nicotine replacement therapies, and e-cigarettes. Psychosocial interventions, such as motivational interviewing, are also discussed.

You can earn 1.0 CME credit here.

Using E-Cigarettes: What Clinicians Must Know

  • E-cigarettes may be safer than cigarettes but are not risk free.
  • Clinicians and patients must be aware of the emergence of vaping-related lung disease.
  • E-cigarettes may be a viable smoking cessation strategy compared with NRT. Learn more.

Quick Takes: Informing Your Practice

Treatment Recommendations for Tardive Dyskinesia

  • Second-generation antipsychotics still produce TD rates around 20%. What can be done? VMAT2 inhibitors emerge as first-line treatments in a recent review. Learn more.

Efficacy and Safety of Deep TMS for OCD

  • In subjects who had a poor response to at least 1 previous SRI, deep TMS for obsessive-compulsive disorder was better than sham TMS but not by much. There was company sponsorship for the study. Learn more. Listen to or read the full volume, and earn 0.5 CME credits here.
Free Files
Success!
Check your inbox, we sent you all the materials there.
Continue in the website
Instant access modal

Become a Bronze, Silver, Gold, Bronze extended, Silver extended or Gold extended Member.

2025–26 Psychopharmacology CME Program

Unlock up to 155 CME Credits, including 40 SA CME Credits.